文献速递关节外科

全髋与全膝关节置换术中切口内万古霉素的系统综述与Meta分析:呼吁开展前瞻性随机试验

Systematic Review and Meta-Analysis of Intrawound Vancomycin in Total Hip and Total Knee Arthroplasty: A Call for a Prospective Randomized Trial.
PubMed 文献 · J Arthroplasty · 2019-04-01

该系统综述与Meta分析检索PubMed和MEDLINE,纳入6项低质量回顾性研究(III级证据)、共3298例患者,其中1801例接受切口内万古霉素。结果显示万古霉素组假体周围关节感染(PJI)发生率降低(OR 0.2530,P<.0001),但证据质量低,作者呼吁在广泛推荐前开展随机对照试验。

要点

  • 切口内万古霉素组PJI发生率降低(OR 0.2530,P<.0001),但仅基于6项低质量回顾性研究。
  • 全膝关节置换术(TKA)与全髋关节置换术(THA)亚组分别显示PJI降低(OR 0.3467,P=.0005;OR 0.3672,P=.0072)。
  • 作者认为切口内万古霉素可能降低PJI风险,但强调需随机对照试验后才能推荐广泛使用。

核心结论

  • 切口内万古霉素可能降低初次和翻修全髋与全膝关节置换术的PJI风险,但仅存在低质量证据,在推荐广泛采用前需开展随机对照试验。

研究设计与样本

  • 检索PubMed和MEDLINE数据库,纳入在初次和翻修全髋与全膝关节置换术中使用切口内万古霉素的研究。
  • 从91项研究中纳入6项低质量回顾性研究(III级证据)进行合并分析,共3298例患者,其中1801例接受切口内万古霉素。
  • 采用随机效应模型合并术后感染数据,以比值比(OR)和95%置信区间报告,研究按效应估计值的方差倒数加权。

主要发现

  • 接受万古霉素的患者PJI发生率降低(OR 0.2530,P<.0001)。
  • TKA患者接受切口内万古霉素后PJI发生率较低(OR 0.3467,P=.0005)。
  • THA患者接受切口内万古霉素后PJI发生率较低(OR 0.3672,P=.0072)。
  • 合并初次TKA和THA患者接受万古霉素后PJI发生率降低(OR 0.4435,P=.0046)。
  • 合并翻修TKA和THA患者感染率出现类似降低(OR 0.2818,P=.0013)。

关键数值与推荐

  • 未观察到明显的发表偏倚。
  • 分析结果受证据质量低和固有潜在偏倚的限制。

临床怎么用

  • 作者认为切口内万古霉素可能降低初次和翻修全髋与全膝关节置换术的PJI风险。
  • 作者指出仅存在低质量证据,强调在推荐广泛采用该做法前需开展随机对照试验。

局限性

  • 纳入的6项研究均为低质量回顾性研究(III级证据)。
  • 分析结果受证据质量低和固有潜在偏倚的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Topical intrawound vancomycin has been used extensively in spine surgery to decrease surgical site infections. However, the efficacy of intrawound vancomycin in total hip (THA) and total knee arthroplasty (TKA) to prevent periprosthetic joint infection (PJI) has not been established. METHODS: The PubMed and MEDLINE databases were searched to identify studies utilizing intrawound vancomycin in primary and revision THA and TKA. Data for postoperative infection were pooled using random effect models with results reported as odds ratios (ORs) and 95% confidence intervals. Studies were weighted by the inverse variance of their effect estimates. RESULTS: Of the 91 studies identified, 6 low-quality retrospective studies (level III) were pooled for further analysis. A total of 3298 patients were assessed, 1801 of which were treated with intrawound vancomycin. Overall, patients who received vancomycin had a decreased rate of PJI (OR 0.2530, P < .0001). When analyzed separately, TKA patients and THA patients who received intrawound vancomycin had lower rates of PJI (OR 0.3467, P = .0005 and OR 0.3672, P = .0072, respectively). Pooled primary TKA and THA patients receiving vancomycin saw the rate of PJI decrease (OR 0.4435, P = .0046). Pooled revision TKA and THA patients saw a similar decrease in infection rates (OR 0.2818, P = .0013). No apparent publication bias was observed; however, the results from this analysis are limited by the low quality of evidence and inherent potential for bias. CONCLUSION: Intrawound vancomycin may reduce the risk of PJI in primary and revision TKA and THA. However, only low-quality evidence exists, highlighting the need for randomized controlled trials before broad adoption of this practice can be recommended given the potential implications of widespread use of vancomycin in hip and knee arthroplasty.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Heckmann ND, Mayfield CK, Culvern CN, et al. Systematic Review and Meta-Analysis of Intrawound Vancomycin in Total Hip and Total Knee Arthroplasty: A Call for a Prospective Randomized Trial. J Arthroplasty. 2019. PMID: 31005433. doi:10.1016/j.arth.2019.03.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。